Related Experiment Video
Updated: Aug 10, 2026
Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
Published on: April 10, 2012
[Change of expression of cell adhesion molecules CD11a and CD49d in patients with chronic aplastic anemia before and
1Department of Hematology, Linyi People's Hospital, Linyi 276003, China.
Insights
Cell adhesion molecules CD11a and CD49d expression decreased in chronic aplastic anemia (CAA) and increased after treatment. Restoring these molecules may improve hematopoietic stem cell function and hematopoiesis in CAA patients.
Area of Science:
- Hematology
- Immunology
- Cell Biology
Background:
- Chronic aplastic anemia (CAA) is a rare bone marrow failure disorder.
- Cell adhesion molecules (CAMs) play roles in cell trafficking and immune responses.
- Altered CAM expression may contribute to the pathogenesis of CAA.
Purpose of the Study:
- To investigate the expression of CAMs CD11a and CD49d in CAA patients.
- To explore the clinical implications of CAM expression in CAA.
- To assess changes in CAM expression following SSL/C therapy.
Main Methods:
- APAAP techniques were used to measure CD11a and CD49d expression.
- Samples included bone marrow (BM) and peripheral blood (PB) mononuclear cells (MNCs).
- 20 CAA patients were studied before and after SSL/C therapy.
Main Results:
- CD11a and CD49d expression in BM MNCs significantly increased post-therapy (P < 0.05).
- CD11a expression in PB MNCs also significantly increased post-therapy (P < 0.05).
- CD49d expression in PB MNCs showed no significant change.
Conclusions:
- Decreased expression of CD11a and CD49d is implicated in CAA pathogenesis.
- Increased CAM expression correlates with effective treatment response.
- Restoration of CAMs may benefit hematopoietic stem cell proliferation, differentiation, and overall hematopoiesis in CAA.
Abstract:
To explore the cell adhesion molecules (CAMs) CD11a and CD49d in patients with chronic aplastic anemia (CAA) and its clinical implications, the expression of CD11a and CD49d in mononuclear cell (MNC) of bone marrow (BM) and peripheral blood (PB) were measured using APAAP techniques in 20 patients with CAA before and after SSL/C therapy. The results showed that the expression of CD11a and CD49d in MNC of BM and CD11a in MNC of PB increased significantly (P < 0.05) after SSL/C therapy, and there was no significant change of CD49d in MNC of PB in both groups. In conclusion, the decrease of CAMs of CD11a and CD49d participated in the pathogenesis of CAA. The expression of CAMs increases with effective treatment, so the restoration or improvement of altered CAMs of CAA might be beneficial to the proliferation and differentiation of hematopoietic stem cell, and improvement of hematopoiesis in CAA.
